58 results
8-K/A
EX-99.1
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
10:53am
Composite (CRc) Rate
Partial Remissions (PRs)
Overall Response Rate (CRc’s + PRs) or ORR
CRc Relapsed or Death to Date
BMT To Date (in CR’s)
See Note 1
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:30am
Composite (CRc) Rate
Partial Remissions (PRs)
Overall Response Rate (CRc’s + PRs) or ORR
CRc Relapsed or Death to Date
BMT To Date (in CR’s)
See Note 1
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
of treatment to the point of disease relapse or death. At the end of January 2024, the Company completed recruiting the desired number of 2nd line subjects … death (suspected to be related to pneumonia) and one relapse to date out of the 9 CRcs. The first subject with a CRc (and who has yet to relapse
424B3
l1tixroc 939x9anl
16 Feb 24
Prospectus supplement
5:19pm
8-K
EX-10.1
gvkomw7q6ug9if4gz
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.3
1d1asvcpg b19yy3a
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.2
o7turrvt
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-3.1
ivrt0bc12614s42
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-3.1
doqlhcetwgcnzbksve
21 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:17pm
S-8
EX-4.5
20ra jzav
21 Jun 23
Registration of securities for employees
5:16pm
S-8
EX-4.5
y6ipvlmdv1 4l8l
19 Jul 22
Registration of securities for employees
5:18pm